Annexon: Perfect Complement To A Speculative Biotech Portfolio

Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome. Learn more about ANNX stock now.

Summary - Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome (GBS). - Tanruprubart achieved highly significant Phase 3 results, with a 2.4-fold GBS-DS improvement versus placebo and strong safety, positioning it for standard-of-care status. - Regulatory filings are underway: MAA was submitted to EMA, with FDA BLA planned for 2026, supported by ongoing FORWARD and real-world evidence studies.

- ANNX’s $225M cash runway extends into H2 2027, supporting key catalysts, with U.S. commercialization planned in-house and ex-U.S. partnerships under consideration. Analyst’s Disclosure: I/we have a beneficial long position in the shares of ANNX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions.

I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I may buy additional shares in ANNX over the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole.

Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party